Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study

doi:10.3748/wjg.v27.i29.4913

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 29

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5825)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

440

WORD

110

HTML

3273

Figures (1-3)

289

Tables (1-3)

298

Sum=4410

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

384

Download

1031

Sum=1415

Aug 7, 2021 (publication date) through Nov 27, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Aug 7, 2021; 27(29): 4913-4928
Published online Aug 7, 2021. doi: 10.3748/wjg.v27.i29.4913

Full Size Figure Download Figure

Figure 1 Flow chart of the selection of the eligible study population in the final analysis. AGE: Advanced glycation end product; NAFLD: Non-alcoholic fatty liver disease.

Citation: Pereira ENGDS, Paula DP, Araujo BP, Fonseca MJMD, Diniz MFHS, Daliry A, Griep RH. Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study. World J Gastroenterol 2021; 27(29): 4913-4928
URL: https://www.wjgnet.com/1007-9327/full/v27/i29/4913.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i29.4913